Aug 28, 2026, 07:00 ETFDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2...
Mounjaro is the first and only GIP and GLP-1 receptor agonist proven to lower heart attack, stroke or cardiovascular death risk in adults with type 2 diabetes at high risk for these events – in...

